TScan Therapeutics (TCRX) Cash from Operations (2020 - 2026)
TScan Therapeutics (TCRX) posted quarterly Cash from Operations of 24279000.0 for Q1 2026, up 35.4% year-over-year from 17930766.39 in Q1 2025, and up 24.13% quarter-over-quarter from 32002000.0 in Q4 2025.
TScan Therapeutics (TCRX) Cash from Operations (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Cash from Operations for 7 consecutive years, with 24279000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 35.4% year-over-year to 24279000.0; the TTM figure through Mar 2026 stood at 122012000.0 (down 2.41% YoY), while the FY2025 annual figure was 135319000.0, down 22.1% from the prior year.
- Cash from Operations advanced to 24279000.0 in Q1 2026 per TCRX's latest filing, from 32002000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 8017000.0 in Q3 2023 and bottomed at 37586000.0 in Q1 2025.
- Historically, Cash from Operations has averaged 23428294.12 across 5 years, with a median of 24279000.0 in 2026.
- Annual changes were most pronounced in 2023 — Cash from Operations jumped 147.15% — and 2024, when it slumped 448.24%.
- TScan Therapeutics' Cash from Operations stood at 16010000.0 in 2022, then tumbled by 48.44% to 23766000.0 in 2023, then declined by 15.34% to 27412000.0 in 2024, then declined by 16.74% to 32002000.0 in 2025, then increased by 24.13% to 24279000.0 in 2026.
- Business Quant data shows TCRX's Cash from Operations at 24279000.0 in Q1 2026, 32002000.0 in Q4 2025, and 32464000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - | -27.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -27.54 Mn |
| Jun 30, 2026 | -27.54 Mn |
| Mar 31, 2026 | -24.28 Mn |
| Mar 31, 2026 | -24.28 Mn |
| Dec 31, 2025 | -32.00 Mn |
| Dec 31, 2025 | -32.00 Mn |
| Sep 30, 2025 | -32.46 Mn |
| Sep 30, 2025 | -32.46 Mn |
| Jun 30, 2025 | -33.27 Mn |
| Jun 30, 2025 | -33.27 Mn |
| Mar 31, 2025 | -37.59 Mn |
| Mar 31, 2025 | -37.59 Mn |
| Dec 31, 2024 | -27.41 Mn |
| Dec 31, 2024 | -27.41 Mn |
| Sep 30, 2024 | -27.92 Mn |
| Sep 30, 2024 | -27.92 Mn |
| Jun 30, 2024 | -26.23 Mn |
| Jun 30, 2024 | -26.23 Mn |
| Mar 31, 2024 | -29.27 Mn |
| Mar 31, 2024 | -29.27 Mn |